Key Points
- Insider sale: Director Derek Maetzold sold 830 shares on Dec. 22 at an average of $40.35 for ~$33,490, trimming his holdings by 2.42% to 33,530 shares (≈$1.35M), per an SEC filing.
- Quarterly beat: Castle reported EPS of ($0.02) vs. a consensus ($0.34) and revenue of $80.55M vs. $71.06M, showing better-than-expected results for the quarter.
- Analyst/ownership backdrop: Several firms raised price targets (e.g., Canaccord, BTIG, Baird) and MarketBeat shows a consensus "Moderate Buy" with a $41 target, while institutional investors hold about 92.6% of the stock.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 830 shares of the business's stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $40.35, for a total transaction of $33,490.50. Following the completion of the transaction, the insider directly owned 33,530 shares of the company's stock, valued at approximately $1,352,935.50. This represents a 2.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Castle Biosciences Stock Down 0.3%
Shares of NASDAQ CSTL opened at $39.27 on Tuesday. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $42.17. The firm's 50 day moving average price is $34.91 and its 200 day moving average price is $25.64. The firm has a market cap of $1.15 billion, a P/E ratio of -87.27 and a beta of 1.14. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%.The company had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. As a group, sell-side analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.
Institutional Trading of Castle Biosciences
Several large investors have recently added to or reduced their stakes in CSTL. AIGH Capital Management LLC acquired a new position in shares of Castle Biosciences during the third quarter worth about $16,105,000. Park West Asset Management LLC purchased a new stake in shares of Castle Biosciences during the 1st quarter valued at about $11,141,000. Braidwell LP lifted its position in Castle Biosciences by 125.3% during the 2nd quarter. Braidwell LP now owns 822,735 shares of the company's stock worth $16,800,000 after acquiring an additional 457,488 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new position in Castle Biosciences during the 3rd quarter worth approximately $9,108,000. Finally, Acadian Asset Management LLC boosted its holdings in Castle Biosciences by 65.4% in the 1st quarter. Acadian Asset Management LLC now owns 676,066 shares of the company's stock worth $13,527,000 after acquiring an additional 267,416 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms recently weighed in on CSTL. Canaccord Genuity Group increased their target price on Castle Biosciences from $37.00 to $50.00 and gave the stock a "buy" rating in a research report on Monday, December 22nd. Robert W. Baird increased their price objective on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an "outperform" rating in a report on Tuesday, November 4th. BTIG Research raised their target price on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a "buy" rating in a research report on Friday, December 12th. Zacks Research raised shares of Castle Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Castle Biosciences in a research note on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $41.00.
Read Our Latest Stock Report on Castle Biosciences
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
